

INV043 EFFECTIVE AGAINST ANAL CANCER SQUAMOUS CELL CARCINOMAS (SCC) IN VITRO**Highlights:**

- *In vitro* study by Peter Mac showed INV043's effectiveness against six squamous cell carcinoma (SCC) cell lines that represent the full range of anal cancers
- Most anal cancers are SCCs and are difficult to treat with the global market estimated to be worth US\$1.3bn by 2028 (6.3% CAGR)
- The Peter Mac study added another clinically important class of tumours to the spectrum of other tumours already shown to be highly sensitive to INV043
- Findings were consistent with the results of work done at the Hudson Institute on other cancer types
- Preclinical testing using topical delivery of INV043 has now started as a prelude to moving to clinical human testing of anal SCC

MELBOURNE (AUSTRALIA) 15 September 2022: Invion Limited (ASX: IVX) ("Invion" or the "Company") is pleased to announce the first set of laboratory results from the Peter MacCallum Cancer Centre (**Peter Mac**) testing INV043 on squamous cell carcinoma (SCC) cell lines, which are linked to anal cancers.

The *in vitro* tests showed that photoactivated INV043 was effective against the six SCC cell lines that cover the spectrum found in anal cancers.

The overall results from this study are consistent with the promising outcomes achieved at the Hudson Institute of Medical Research (**Hudson Institute**) on other cancer types, including triple negative breast cancer.

The global anal cancer market is forecast to grow at a compound annual growth rate (CAGR) of 6.3% to hit US\$1.25 billion (\$1.84 billion) by 2028¹. Anal cancers are particularly difficult to treat and most are SCCs that line the surface of the anal canal.

This latest study, which was done in conjunction with the Hudson Institute and Invion, was led by Professor Robert Ramsay, Group Leader at Peter Mac.

"Investigating INV043 therapy for anal SCC is our immediate focus. SCC cell lines from the full range of anal cancers, from primary to metastatic and molecular subtypes, all respond to the killing action of INV043," said Prof Ramsay.

"Preclinical testing using topical delivery of INV043 has now started as a prelude to moving to clinical testing in patients with anal SCC."

INV043 is Invion's lead drug candidate and represents the next generation of photodynamic therapy that aims to treat multiple types of cancers.

The Chairman and Chief Executive Officer of Invion, Thian Chew, commented:

"Prof Ramsay and his team have now added a different and clinically important class of tumours to the spectrum of other tumours already shown to be highly sensitive to INV043 by the Hudson Institute.

¹ <https://www.coherentmarketinsights.com/market-insight/anal-cancer-market-4701>

ASX ANNOUNCEMENT

"SCCs occur throughout the body, but those associated with the ano-genital regions are particularly hard to manage if they fail first-line therapy."

Details and Results of Study

The core purpose of these studies was to assess the relative cytotoxicity of light activated INV043 of human anal SCC cell lines. These data are a prelude to planned in vivo studies. This was done by:

- Comparing the phototoxicity of a sentinel cell line used in both Hudson Institute (HIMR) and Peter Mac (PMCC) research laboratories, namely immortalised human embryonic kidney cells (HEK)
- Testing phototoxicity of human HPV+ve and -ve anal SCC cell lines
- Testing phototoxicity of a unique mouse anal SCC model developed at the PMCC which comes in two forms: parental line and one with human HPV E6 and E7 oncoproteins. This second line is a faithful mouse version of human HPV+ve anal cancer.

Figure 1 shows relative viability of 6 human anal SCC cell lines established at Peter MacCallum Cancer Centre (PMCC). Additionally, HEK293 GP (liver cancer) data as conducted by the Hudson Institute are embedded to benchmark responses.




Figure 1. Cytotoxicity data of human anal SCC cells lines. Six anal SCC lines derived from tumours were tested.

This announcement was approved for release by the Board of Directors.

Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: brendon.lau@inviongroup.com

ASX ANNOUNCEMENT

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea to the Photosoft™ technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.